Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
Pier Luigi Zinzani, Robert Chen, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz
Abstract
NA
Topics & Concepts
Brentuximab vedotinMedicineRefractory (planetary science)Salvage therapyOncologyPembrolizumabInternal medicineAutologous stem-cell transplantationClassical Hodgkin lymphomaTransplantationLymphomaChemotherapySurgeryHodgkin lymphomaImmunotherapyCancerPhysicsAstrobiologyLymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research